Preventing Liver Cancer: Breaking the Link With Liver Disease

Medical experts are intensifying efforts to prevent liver cancer by targeting its root cause: underlying liver disease. A growing consensus among hepatologists and oncologists emphasizes that preventing conditions like cirrhosis, hepatitis, and fatty liver disease is the most effective strategy to reduce liver cancer incidence and mortality.

“Liver cancer is unique in that 95% of those affected have underlying liver disease,” said Anna Suk-Fong Lok, M.D., Director of Clinical Hepatology and Assistant Dean for Clinical Research at the University of Michigan. “The best way to prevent liver cancer is to prevent liver disease from occurring in the first place.”

This perspective is reinforced by recent clinical guidance from the American Gastroenterological Association, which has updated its recommendations to call for better surveillance of hepatocellular carcinoma, the most common form of liver cancer, particularly in high-risk populations with chronic liver conditions.

Preventing cirrhosis, a late-stage scarring of the liver, is considered the most effective way to reduce liver cancer deaths. Experts note that cirrhosis significantly increases the risk of hepatocellular carcinoma, and managing underlying conditions such as hepatitis B and C, alcohol-related liver disease, and nonalcoholic fatty liver disease can halt or slow its progression.

Public health initiatives are increasingly focused on eliminating viral hepatitis as a primary driver of liver cancer. The Prevention Potential in Eliminating Hepatitis C initiative highlights that treating and curing hepatitis C infection can substantially lower the risk of liver cancer, especially when combined with vaccination programs for hepatitis B and harm reduction strategies for at-risk populations.

For individuals already living with liver disease, regular monitoring and early intervention remain critical. Updated surveillance guidelines recommend more frequent screening for hepatocellular carcinoma in patients with cirrhosis or chronic hepatitis, using ultrasound and alpha-fetoprotein testing every six months to detect cancer at an early, treatable stage.

While advances in treatment have improved outcomes for some liver cancer patients, prevention through liver disease management remains the cornerstone of reducing mortality. As research continues to uncover the complex links between metabolic disease, viral infection, and liver carcinogenesis, public health strategies are evolving to address multiple risk factors simultaneously.

As liver cancer rates continue to rise globally, driven in part by increasing prevalence of obesity, diabetes, and viral hepatitis, the message from experts is clear: breaking the link between liver disease and cancer begins with prevention, early detection, and equitable access to care for all at-risk populations.